Skip to main content

Peer Review reports

From: Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

Original Submission
31 Dec 2020 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
21 Jan 2021 Reviewed Reviewer Report
22 Jan 2021 Reviewed Reviewer Report - Egilius L H Spierings
25 Jan 2021 Reviewed Reviewer Report - Andrew M. Blumenfeld
9 Feb 2021 Author responded Author comments - David Kudrow
Resubmission - Version 3
9 Feb 2021 Submitted Manuscript version 3
13 Feb 2021 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
18 Feb 2021 Editorially accepted
19 Mar 2021 Article published 10.1186/s12883-021-02123-w

You can find further information about peer review here.

Back to article page